Niedermaier T, et al. - Among 435 individuals with newly diagnosed colorectal cancer (CRC), researchers sought to determine stage- and location-specific sensitivities of a quantitative fecal immunochemical test (FIT). They obtained fecal samples before treatment from patients with newly diagnosed CRC. The FIT detected T1 tumors with 52% sensitivity, T2 tumors with 79% sensitivity, T3 tumors with 93% sensitivity, and T4 tumors with 84% sensitivity at the cutoff recommended by the manufacturer. The FIT identified stage I cancers with 68% sensitivity, stage II cancers with 92% sensitivity, stage III cancers with 82% sensitivity, and stage IV cancers with 89% sensitivity. Although the FIT recognizes patients with CRC with high overall sensitivity, about one-third of stage I CRCs can be missing. Investigations are required to increase noninvasive detection of early-stage CRC.